Ankylosing spondylitis causes persistent back pain, spinal stiffness, and progressive functional impairment, with a substantial proportion of patients failing to achieve adequate disease control with current biologic therapies - creating a critical unmet need for more durable and effective long-term treatments. Dual inhibition of IL-17A and IL-17F provides an optimized therapeutic approach to suppress amplified inflammatory signaling that drives axial inflammation and irreversible spinal damage. In a pivotal 52-week Phase III trial, XKH004, an innovative China-developed dual-target IL‑17A/F monoclonal antibody, yielded robust, sustained improvements in disease activity, physical function, pain relief, and quality of life in patients with active ankylosing spondylitis. These long-term clinical outcomes validate XKH004’s potent efficacy and favorable safety profile, establishing it as a promising next-generation biologic option for refractory and suboptimally controlled ankylosing spondylitis.

Electrochemical CO₂ reduction offers a promising route to convert CO₂ into valuable fuels and chemicals using renewable electricity. However, most current systems rely on high-purity CO₂ feeds, whereas practical carbon sources such as industrial flue gas and air contain much lower CO₂ concentrations together with impurities including O₂, SO_x and NO_x. A team of scientists has reviewed recent advances in electrochemical capture and conversion of dilute CO₂. The review highlights two major strategies, integrated CO₂ capture and conversion and direct electrolysis of dilute CO₂, and discusses how catalyst design and electrolyzer engineering can work together to move the technology toward practical applications. Their work is published in the journal Industrial Chemistry & Materials on July 15, 2026.

The continuous threat of mutating viral strains demands effective broad-spectrum mucosal vaccines, but delivering multivalent antigens across respiratory barriers remains a major challenge. To overcome these physiological hurdles, a research team developed a novel mucosal vaccine platform utilizing gold nanoparticles (AuNPs). By co-displaying multiple Betacoronavirus antigens on AuNPs optimized to penetrate respiratory barriers, this "mosaic" vaccine significantly enhances antigen uptake and retention in the lungs. When administered intranasally alongside an adjuvant, the multivalent AuNP-Mix elicited robust local mucosal immunity, prominently inducing high levels of secretory IgA and activating lung tissue-resident memory T (TRM) cells. This response effectively generated cross-neutralizing antibodies against various strains and established comprehensive, long-lasting mucosal B and T cell memory. This innovative delivery system offers a highly promising strategy for the development of next-generation broad-spectrum mucosal vaccines capable of defending against diverse coronaviruses.

This comprehensive review establishes the existing methods and effectiveness of lithium ion battery recycling while putting forth a proposal for the future of lithium ion battery recycling. This proposed mechanism will include artificial intelligence powered diagnoses of the cathode materials to determine the failure features of the cathode and the optimal way to recycle the materials within, as well as the facility to sort the recyclable materials within one facility to establish a closed-loop system.